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The peptidyl prolyl cis–trans isomerase Pin1 and the Inhibitor of Apoptosis Protein (IAP) Survivin are two major proteins involved in cancer.
They both modulate apoptosis, mitosis, centrosome duplication and neuronal development but until now no functional relationship has been
reported between these two proteins. We tested Pin1-induced regulation of Survivin in neuroblastoma cells. Pin1 overexpression in SY5Y
neuroblastoma cells decreased Survivin levels. Immunocytochemical studies indicated that they partially co-localized in interphase and mitotic
cells. Co-immunoprecipitation further demonstrates the existence of a Pin1/Survivin complex. Pin1-induced effect on Survivin was confirmed in
COS cells. RT-PCR and mutagenesis experiments suggested that this Pin1-induced decrease of Survivin occurred at the protein level. Survivin
downregulation depended on the binding ability of Pin1 but was not related to the single Thr–Pro site, suggesting an indirect relationship into a
protein complex. Finally, this functional regulation of Survivin by Pin1 is reciprocal since Pin1 silencing led to an increase in Survivin levels. The
characterization of this functional relationship between Pin1 and Survivin might help to better understand mitosis control and cancer mechanisms.
© 2007 Elsevier B.V. All rights reserved.Keywords: Cell cycle; Mitosis; Neuroblastoma; WW domain; PPIase; Cancer1. Introduction
The peptidyl–prolyl cis/trans isomerase Pin1 recognises
specific motifs consisting of a phosphorylated Ser or Thr residue
preceding a Pro (p(Ser/Thr)–Pro motifs) [1,2]. It catalyses the
conformational change of the peptide bond between cis and trans
conformations. Pin1 has two domains, a N-terminal type IVWW
domain and a C-terminal catalytic domain. TheWW domain is a
protein interacting domain that targets Pin1 to its substrates,
whereas the catalytic domain isomerises specific pSer/Thr–Pro
motifs [3].
Pin1 is of particular interest in pathogenesis of human dis-
eases, most notably cancer and Alzheimer's disease. A hallmark
of the latter is the aggregation of hyperphosphorylated forms of
the microtubule associated Tau protein. Pin1 was first described
as a new regulator of phosphorylation and conformation of Tau
proteins [4]. In vitro Pin1 binds to and isomerises pThr–Pro⁎ Corresponding author. Tel.: +33 320 622074; fax: +33 320 622079.
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conformation by PP2A [5–8]. In situ, in SY5Y neuroblastoma
cells and primary cortical mouse culture, Pin1 facilitates a dif-
ferential dephosphorylation of Tau at pThr231 [9,10]. Further-
more, some hypotheses state that Pin1 could regulate some
cell cycle markers which are altered in Alzheimer's disease
[11,12]. In fact, Pin1 induces Cyclin D1 expression at the
transcriptional and protein levels [13–16]. This could favour
cell cycle entry for proliferating oncogenic cells or re-entry for
differentiated neurons. Pin1 also regulates a large number of
mitosis-specific phosphoproteins in proliferating cells, many
phosphorylated by Cdc2 [17,18]. Pin1 deletion leads to mitotic
block and apoptosis [19]. Therefore, Pin1 could help with co-
ordinating mitotic events by regulating the function of mitotic
phosphoproteins.
Survivin is another major protein involved in mitosis control.
Survivin expression increases during the G2-M phases and it is
used as a G2-M cell cycle marker [20,21]. It is part of a chro-
mosomal passenger complex which controls chromosome
alignment, sister chromatid segregation and cell division [22].
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cancer, especially because, as a member of the Inhibitor of
Apoptosis Protein (IAP) family, it can inhibit apoptosis [23].
Pin1 has also been implicated in apoptosis by interacting with
proteins like p53 or BIMEL [24–26]. Finally both proteins are
involved in brain development. Survivin deletion in early brain
development is lethal with massive loss of neurons [27]. Pin1
increases during neuronal differentiation and neurons are the
only known differentiated cells where Pin1 is expressed [9].
These similarities between Pin1 and Survivin have led us to
investigate their relationships. First, the effect of Pin1 over-
expression on Survivin was investigated in a new Pin1-inducible
SY5Y cell model. Immunocytochemistry and immunoprecipita-
tion experiments were carried out to study co-localization of
both Survivin and Pin1 in neuroblastoma cells. Finally, both
Pin1 binding ability and Pin1-induced modulation of Survivin
were dissected in COS cells by transfection of different cDNA
constructs and Pin1-directed shRNA, proteasome inhibitor
treatment and RT-PCR.2. Materials and methods
2.1. Cell culture and transfection
Pin1 inducible human neuroblastoma cells were generated as described in
[10] from native neuroblastoma SH-SY5Y cells. For induction of Pin1
expression, cells were maintained in medium with tetracycline at 1 μg/mL.
Pin1 and Survivin human cDNA [10,28] were subcloned into pcDNA4To
(Invitrogen) and transfected using ExGen500 (Euromedex, France). COS-7 cells
were grown as previously described. Transient transfection was performed in six-
well plates. Mutant Pin1 Ser16Glu and Survivin Thr34Ala were generated by
PCR using the quikChange™ Site-Directed Mutagenesis kit (Stratagene) with
the forward primer 5′-GG GAG AAG CGC ATG GAG CGC AGC TCA GGC
CG-3′, the reverse primer 5′-CG GCC TGA GCT GCG CTC CAT GCG CTT
CTC CC-3′ and the forward primer 5′-GCC TGC GCC CCG GAG CGG ATG
GCC-3′, the reverse primer 5′-GGC CAT CCG CTC CGG GGC GCA GGC-3′
respectively. A GFP-expressing plasmid was transfected concomitantly to the
cells to estimate transfection efficiency. When necessary, an empty pcDNA4
vector was used to cotransfect the same amount of DNA in each condition.
Proteasome inhibition was carried out with epoxomicin (Calbiochem).
Conditions were determined by testing 0.5 μM, 1 μM during 12 h and 24 h.
Finally we performed the experiments at 1 μM for 12 h.
A siRNA sequence from a set of human Pin1 siRNA duplexes (siGenome
duplexesMQ-003291-02-05, DHARMACON) was used as a basis for designing
a human Pin1-directed shRNA. Complementary oligonucleotides were annealed
and inserted into a linearized shRNA expression vector (RNAi-Ready pSIREN-
Shuttle from BD Biosciences). A negative control shRNA annealed nucleotide
(PT3739-1, BD Biosciences) was used to construct the control vector.
2.2. Western blotting
Neuroblastoma cells were harvested with Versene (EDTA, Gibco) and
centrifuged. Cell pellets were lysed in ice-cold modified RIPA buffer (50 mM
Tris, pH 7.4, 1% Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 0.5% DOC, 0.1%
SDS) containing protease inhibitors (Complete mini; Roche), 1 mMNa3VO4 and
125 nM okadaic acid (Sigma). The samples were sonicated and stirred 1 h at 4 °C.
Cell lysate was recovered in supernatant after centrifugation at 12,000×g at 4 °C
for 20 min. Protein concentration was determined by the BCA protein assay kit
(Pierce). Samples were mixed with an equal volume of 2× Laemmli buffer and
40 mM dithiothreitol, heated for 5 min at 100 °C and 10 μg were loaded onto
SDS-PAGE gel. Transiently transfected COS-7 cells were scraped directly in
100 μL 1× Laemmli buffer and 20 mM dithiothreitol, sonicated and heated.
10 μL was loaded onto SDS-PAGE gel. Electrophoresis and transfer on nitro-cellulose membrane (Amersham) were done with the NuPAGE® electrophoresis
system, using the Xcell SureLock™ Mini-Cell and the Xcell II™ Blot Module
(Invitrogen). 4–12%Bis–Tris gels were used.Membraneswere blocked in TBST
(Tris Buffer Saline Tween, 10 mMTris–HCl pH 8, 150 mMNaCl, 0.05% Tween
20) with 5% skimmed milk and incubated with primary antibody. Horseradish
peroxidase-conjugated antibody (Sigma) was used as secondary antibody, and
horseradish peroxidase activity was detected with the ECL detection kit
(Amersham Biosciences). Western blots were quantified by densitometry with
the IMAGE-MASTER 1D ELITE software (Amersham Biosciences). Results
were expressed as means±S.E.M of at least three independent experiments.
Statistics were performed using t tests with two-tail P values.
2.3. Antibodies
Survivin monoclonal antibodies (6E4 Cell Signaling Tech., Ozyme, France,
D-8, Santa Cruz Biotech, Tebu-Bio, France), Survivin polyclonal antibody (FL-
142, Santa Cruz Biotech), Cyclin D rabbit polyclonal antibody that recognises
Cyclin D1 (#06-137, Upstate, Euromedex, France), Neuronal Specific γ-Enolase
(NSE) polyclonal antibody (Santa Cruz Biotech), Pin1 polyclonal antibody
(H123, Santa Cruz Biotech), GAPDH polyclonal antibody (FL-335, Santa Cruz
Biotech), GFP monoclonal antibody (B-2, Santa Cruz Biotech).
2.4. Immunocytochemistry
Cells were fixed in a 4% paraformaldehyde PBS solution 30 min at room
temperature. After washing with PBS, cells were permeabilized in 0.25%
Triton x100 PBS solution 10 min at room temperature. After washing, non-
specific binding sites were blocked in PBS containing 2% bovine serum
albumin 1 h at room temperature. Primary antibody was then added in bovine
serum albumin solution for 2 h at room temperature. After washing, cells were
incubated with the secondary antibody (Alexa Fluor 488® Molecular Probes) in
PBS for 45 min. After washing, nuclei were stained with DAPI (1 μg/mL in
PBS) for 5 min. Samples were then mounted using Vectashield mounting
medium and viewed with a fluorescent optical microscope (LEICA DMRB), a
fluorescent confocal microscope (LEICA TCS NT) and by ApoTome (Carl
Zeiss). Z-sections are shown. Specificity of the secondary antibody alone was
checked.
2.5. Immunoprecipitation
Cell lysates (Pin1 expressing cells treated 48 h with tetracycline) were
prepared as described under “Western blotting” but with NP-40 lysis buffer
(50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.1% NP-40). 1 mg of
cell lysates (200 μL at 5 mg/ml) was incubated with the immunoprecipitating
antibody (2 μL Survivin 6E4 and 0.6 μg Survivin D-8) overnight at 4 °C and
then incubated 2 h at 4 °C with 20 μl of anti-mouse IgG beads (TrueBlot Ig Ip
Beads, eBioscience). Immunoprecipitated complexes were washed three times
with lysis buffer (centrifugation at 1000×g at 4 °C for 5 min), recovered in 25 μL
of 2× Laemmli buffer with 100 mM of fresh dithiothreitol, boiled for 5 min, and
then loaded onto SDS-PAGE gel and analyzed by immunoblotting.
2.6. Flow cytofluorometry analysis
Cells were harvested with Versene in PBS. A fraction was analyzed by
western blotting to check for Pin1 overexpression. Cells were fixed by adding
−20 °C absolute ethanol (ratio 5/1 with PBS). After washing with PBS, RNA
was degraded by treatment with 1 unit/mL RNAse A (Sigma) for 15 min at
room temperature. Cells were permeabilized by triton x100 0.1%, stained with
50 μg/mL propidium iodide for 45 min and analyzed by a fluorescence-
activated cell sorter (Epics Altra Beckman Coulter). Results were processed by
Expo 32 software (Beckman Coulter) and Multicycle AV (Phoenix Flow
system).
2.7. RT-PCR
Purification of mRNA was performed using the NucleoSpin® RNA II kit
(Macherey-Nagel) from 6 well dish of transfected COS cells. The reverse
Fig. 1. Effect of Pin1 overexpression on Survivin levels in neuroblastoma cells.
(A) Western blots using anti-Pin1, anti-Cyclin D1, anti-Survivin 6E4 and anti-
NSE antibodies of cell lysates from mock or Pin1 inducible SY5Y cells in
absence (Tet −) or presence (Tet +) of tetracycline for 48 h. (B) Tetracycline
treatment induced a Pin1 overexpression in inducible cells. (C) Functional effect
of Pin1 overexpression was verified with Cyclin D1 immunostaining. (D)
Survivin levels were decreased when Pin1 was overexpressed. NSE immuno-
labelling is used as an internal loading control for the quantification (⁎pb0.05;
⁎⁎⁎pb0.001).
Fig. 2. Survivin labelling specificity. (A) Western blots using anti-Pin1, anti-
Survivin 6E4, anti-Survivin D-8, anti-Survivin FL-142 and anti-NSE antibodies
of cell lysates from mock or Pin1 inducible SY5Y cells in absence (Tet −) or
presence (Tet +) of tetracycline for 48 h. (B) NSE immunolabelling is used as an
internal loading control for the quantification (⁎pb0.05).
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semiquantitative PCR with the DyNAzyme™ EXT polymerase (Finnzyme)
under experimental conditions allowing the linearity of amplifications, using the
forward primer 5′-ATGGGTGCCCCGACGTTGCCC-3′ and the reverse primer
5′-TCAATCCATGGCAGCCAGCTGCTCG-3′ for Survivin and the forwardprimer 5′-AAACGGCTACCACATCCAAG-3′ and the reverse primer 5′-
CGCTCCCAAGATCCAACTAC-3′ for 18S. PCR products were separated on
2.5% agarose gels and bands were quantified by densitometry as described
above.3. Results
3.1. Modulation of Survivin levels in Pin1-expressing SY5Y
cells
The expression of Pin1 was analyzed in mock SY5Y and
Pin1-inducible SY5Y neuroblastoma cells. As seen in Fig. 1A
and B, Pin1 was only slightly detected in mock SY5Y cells.
Pin1 inducible cells displayed a low basal expression of
transgene protein. Conversely, tetracycline treatment induced a
strong Pin1 overexpression in these cells.
Pin1 is well known to stabilize Cyclin D1 in mitotic cells
[11,13]. To validate the Pin1 inducible cell model, Cyclin D1
levels were investigated. Pin1 overexpression increased Cyclin
D1 immunoreactivity by 75% validating the present cell model
(Fig. 1A, C). In the same conditions, Survivin levels were
statistically decreased by 50% suggesting an inverse correlation
(Fig. 1A, D). To ascertain the specificity of Survivin decrease,
two different monoclonal antibodies and one polyclonal
antibody were tested. All antibodies showed a Pin1 over-
expression-induced Survivin decrease (Fig. 2). Since Survivin is
a G2/M marker, we investigated if Pin1 overexpression alters
Fig. 3. Pin1 effect on G2-M phases in neuroblastoma cells. Cell cycle repartition of inducible Pin1 cells in absence or presence of tetracycline treatment for 48 h was
determined by flow cytometry. G2-M phase cell number was not statistically different.
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work, no significant change could be seen by flow cytometry in
the G2-M repartition of Pin1 overexpressing neuroblastoma
cells (Fig. 3).
3.2. Pin1 and Survivin interactions
To investigate the distribution of Pin1 and Survivin in SY5Y
neuroblastoma cells, both proteins were analyzed by immuno-
cytochemistry (Figs. 4 and 5). A weak Survivin labelling was
detected in nucleus and cytoplasm of interphase cells (Fig. 4B).
The anti-Pin1 antibody labelled the nucleus and more slightly
the cytoplasm (Fig. 4A). Ten to 20% co-localization could be
observed in the nucleus and cytoplasm of interphasic cells by
ApoTome and confocal microscopy. Moreover anti-Survivin
antibody sharply stained mitotic cells in comparison with
interphasic cells (Fig. 5A2). Chromosomes of prophase and
metaphase (Fig. 5B3), central spindle of anaphase (Fig. 5C3)
and midbodies of telophase (Fig. 5D3) were typically labelled,
supporting a specific labelling of Survivin [29]. Pin1 antibody
stained the whole cell except the chromosomes (Fig. 5B2, C2,
D2). Colocalization was observed on the central spindle inFig. 4. Co-localization of Pin1 and Survivin in SY5Y interphasic cells. Double immu
observed by ApoTome. (A) Pin1 labelling, (B) Survivin labelling, (C) DAPI labellinanaphase (Fig. 5C4) and on the midbodies of telophase
(Fig. 5D4).
Since co-localization was observed between Pin1 and
Survivin, we investigated a potential interaction by carrying
out immunoprecipitation experiments. Survivin was immuno-
precipitated with two different anti-Survivin antibodies in Pin1-
inducible SY5Y cells (Fig. 6). Pin1 was detected in both
immunoprecipitates. Survivin or Pin1 were not detected in con-
trol immunoprecipitation of lysate without anti-Survivin anti-
body. This result suggested that both Survivin and Pin1 could be
part of a common protein complex.
3.3. Pin1 Ser16–Glu mutation impairs Pin1-induced Survivin
decrease in COS cells
To further investigate the interaction of Pin1 and Survivin,
different cDNA constructs were transfected in COS cells. Pin1
and Survivin cDNAs co-transfection significantly decreased
Survivin levels (Fig. 7A lane 2), compared to transfection of
Survivin cDNA alone (Fig. 7A lane 1). These results confirmed
Pin1-induced Survivin reduction observed in SY5Y. Pin1 capa-
city to bind its substrates was further studied by mutating Ser 16nostaining with anti-Survivin 6E4 and anti-Pin1 H123 antibodies of SY5Y cells
g, (D) merge.
Fig. 5. Co-localization of Pin1 and Survivin in SY5Ymitotic cells. Double immunostaining with anti-Survivin 6E4 and anti-Pin1 H123 antibodies of SY5Y cells. (B1),
(C1) and (D1) were observed by optical microscopy whereas the others were observed by confocal microscopy at low magnification (A) or high magnification (B–D).
For (B1), (C1) and (D1), top left Pin1 labelling, top right Survivin labelling, bottom left DNA (DAPI labelling), bottom right merge. (A1), (B2), (C2) and (D2) Pin1
labelling, (A2), (B3), (C3) and (D3) Survivin labelling and (A3), (B4), (C4) and (D4) merge. (A) shows an asynchronous fields, where mitotic cells (arrow) are more
labelled by Survivin antibody than interphase cells (A2). (B) In metaphase cells, Survivin labelling was high and mainly on chromosomes (arrow and B1). Pin1 did not
co-localize on chromosomes. (C) In anaphase cells, Survivin antibodies no more labelled chromosomes but the central spindle (arrow) as well as Pin1 antibodies. Pin1
stained the whole cytoplasm except chromosomes. (D) In telophase/cytokinase cells, Survivin and Pin1 colocalized on midbodies (arrow). Pin1 labelling was also
localized in the cytoplasm.
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Fig. 6. Co-immunoprecipitation of Pin1 and Survivin in SY5Y cells. Immuno-
precipitation of Survivin in a SY5Y cell lysate from Pin1 overexpressing cells
(48 h of tetracycline treatment) with anti-Survivin 6E4 and anti-Survivin D-8
antibodies. The blot was probed with Pin1 antibody and then reprobed with anti-
Survivin 6E4 antibody. Pin1 is coimmunoprecipitated with Survivin. ⁎ Remain-
ing staining of Pin1 during anti-Survivin immunoblotting.
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In fact, glutamate mimics the phosphorylation state of Ser16 and
prevents Pin1 binding to its targets [30]. Co-transfection ofFig. 7. Co-transfection of Pin1 and Survivin in COS cells. (A)Western blotting of cell l
Survivin andwild type Pin1 (lane 2) and Survivin andmutated Pin1 S16E (lane 3). GFP
control. Co-transfection of cDNAs coding for both Pin1 and Survivin decreased Surviv
altered Survivin protein level but to a lesser extent. (⁎pb0.05 ; ⁎⁎⁎pb0.001). (B) The
similar (⁎pb0.05 ; ⁎⁎pb0.01).cDNAs coding for Pin1 mutant instead of wild type Pin1
significantly prevented Survivin decrease (Fig. 7A lane 3). This
result suggested that Pin1 binding capacity is necessary to
modulate Survivin levels.
3.4. SurvivinThr34–Ala mutation does not prevent
Pin1-induced Survivin decrease in COS cells
Since Pin1 and Survivin are in the same protein complex, they
may interact directly. Interestingly, Survivin possesses only one
Ser/Thr–Pro motif located at Thr34–Pro35, which may be the
Pin1 binding site. Thr34 is phosphorylated by Cdc2–Cyclin B
during G2-M phases [31]. Inhibition of Thr34 phosphorylation
reduces Survivin stability [20,32]. Regulation of this pathway
facilitates the elimination of cancer cells at mitosis [33,34]. As
with Tau or Cdc25 [5], by isomerising pThr34–Pro35 bond, Pin1
could facilitate dephosphorylation of Survivin pThr34 and
modulate Survivin stability. To test this hypothesis, we mutated
Survivin Thr34 into Ala, a mutant that cannot be phosphorylated.
Surprisingly, co-transfection of Pin1 with Thr34–Ala mutant still
decreased the level of this mutant (Fig. 7B lane 2). Thus, the
functional effect of Pin1 on Survivin levels is likely to be un-
related to a direct physical interaction between the two proteins.ysates. COS cells were transfectedwith cDNAs coding for Survivin alone (lane 1),
was cotransfected each time as transfection control. GAPDH is used as a loading
in protein level. Co-transfection of cDNAs coding for Survivin andmutated Pin1
same experiment was carried out with mutated Survivin Thr34Ala. Results were
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on proteasome-mediated Survivin degradation in COS cells
Since the interaction is likely to be indirect, we investigated
how Pin1 could regulate Survivin levels. Pin1 has already been
shown to regulate mRNA stability [35] and transcription by
interacting with RNA polymerase II [36]. To check if Pin1-
induced Survivin regulation occurred at the transcription level,Fig. 8. Effect of Pin1 overexpression on Survivin mRNA and on Survivin degradatio
coding for Survivin alone (lane 1), Survivin and Pin1 (lane 2), Pin1 alone (lane 3) an
and Survivin did not alter Survivin RNA levels. (B) Western blotting of cell lysates. C
Pin1 alone (lane 2), Survivin alone (lane 3 and 5), Pin1 and Survivin (lane 4 and 6). A
and 6). Epoxomicin treatment increased Survivin and ubiquitinated Survivin levels b
the ratio of ubiquitinated Survivin out of Survivin increased in Pin1 overexpressionSurvivin mRNA amount was analyzed by semi-quantitative RT-
PCR (Fig. 8A). Pin1 and Survivin cDNA co-transfection did not
lower Survivin mRNA (Fig. 8A lane 2), suggesting that Pin1-
induced Survivin protein decrease is not related to changes in
mRNA levels. Thus, Pin1-induced Survivin regulation is likely
to occur at the protein level.
Survivin is known to be degraded by the proteasome [37]. To
test if Pin1 could regulate Survivin level by acting on itsn by the proteasome in COS cells. (A) COS cells were transfected with cDNAs
d with an empty vector (lane 4). Co-transfection of cDNAs coding for both Pin1
OS cells were transfected with an empty vector (lane 1), with cDNAs coding for
t the end of the transfection, epoxomicin (1 μM) was added to the medium (lane 5
ut did not abolish Pin1 overexpression-induced Survivin decrease. Nevertheless,
condition (lane 6) (⁎pb0.05).
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with the proteasome inhibitor epoxomicin (Fig. 8B) [38]. Pro-
teasome inhibition led to an increase of Survivin and ubiquitinated
Survivin levels in the presence or absence of Pin1 overexpression
but could not completely abolish Pin1 overexpression-induced
Survivin decrease. However, when treated with epoxomicin, the
ratio ubiquitinated Survivin on Survivin was increased when Pin1
was overexpressed (Fig. 8B lane 6 versus 5 and Fig. 8C),
indicating that Pin1 could partially modulate Survivin regula-
tion by the ubiquitin–proteasome pathway as observed for
cyclinE–SCF ubiquitin ligase complexes [39].
If Pin1 facilitates Survivin degradation, one may ask if there
is an increase of Survivin in the absence of Pin1.
3.6. Pin1-directed shRNA inhibits Pin1-induced Survivin
decrease in COS cells
After Pin1 overexpression, the reciprocal effect of Pin1
silencing on Survivin levels was investigated (Fig. 9). Survivin
expression plasmid and Pin1-directed shRNA vector were
transfected in COS cells. This co-transfection led to a significant
increase of Survivin (Fig. 9 lane 2). Furthermore, co-transfec-
tion of the Pin1-directed shRNA vector with both Pin1 and
Survivin cDNAs reduced Pin1 overexpression and partially
restored Survivin expression (Fig. 9 lane 4). These results
confirm a negative correlation between Pin1 and Survivin
levels. All together, it suggests that Pin1 can modulate Survivin
levels.Fig. 9. Effect of Pin1 silencing on Survivin level in COS cells. Western blotting
of cell lysates. COS cells were transfected with cDNAs coding for Survivin alone
(lane 1), Survivin and Pin1-directed shRNA (lane 2), Survivin and Pin1 (lane 3),
Survivin Pin1 and Pin1-directed shRNA (lane 4). Co-transfection of cDNA
coding for Pin1-directed shRNA decreased overexpressed Pin1 level and
increased Survivin protein level. GAPDH is used as a loading control (⁎pb0.05).4. Discussion
The relationship between Pin1 and Survivin has been
investigated in neuronal cells. In SY5Y neuroblastoma cells,
overexpression of Pin1 decreased Survivin levels. This effect
could be reproduced by transient transfection in COS cells.
Conversely, Pin1-directed shRNA increased Survivin levels.
Therefore Pin1 expression is able to modulate Survivin levels.
These results show for the first time a functional relationship
between Pin1 and Survivin, two major proteins involved in
human cancers.
Pin1 or Survivin are overexpressed in many tumors [40,41]
and are usually negative prognostic factors [42,43]. They are
both promising therapeutic targets [44,45]. Pin1 amplifies many
pro-proliferative signallings in cancer cells and its inhibition
would provide a way of tackling simultaneously multiple
oncogenic signal pathways at several levels [46]. Survivin
may greatly be involved in the chemo- and radio-resistance of
tumour cells and its inhibition could drive cancerous cells to
death by increasing their sensitivity to chemical and physical
agents [44]. Our results point out that acting on Pin1 might
modulate Survivin levels. It should be taken into consideration
for therapeutic strategies.
Pin1 has been previously reported to regulate the cellular
decrease of various proteins like cyclin E, c-Myc or Pim1 [47–
49]. Nevertheless, the negative regulation of Pin1 on Survivin is
particularly intriguing. It does not fit with reported over-
expression and pro-oncogenic role of both proteins in cancers.
However until now there is no evidence showing that Pin1 and
Survivin are concomitantly overexpressed in the same tumoral
cells. If Pin1-induced decrease of Survivin occurs in neuro-
blastoma, it should lead to tumour regression. To this point,
noticeably, occurrence of neuroblastoma spontaneous regres-
sions has been reported [50]. Recently Pin1 has been shown to
increase during neuroblastoma differentiation, suggesting a role
of Pin1 overexpression in neuronal differentiation [9]. In
neuroblastoma cells, Pin1 increase might have a dual role and
promote either oncogenesis or differentiation. Moreover, Pin1
might facilitate physiological cell cycle-related down-regulation
of Survivin levels. This mechanism could be altered in cancer
favouring Survivin overexpression. Further studies will be
necessary to explore these aspects.
Pin1 has been recently shown to regulate GM-CSF mRNA
stability [35,51] and transcription by interacting with RNA
polymerase II [36]. RT-PCR experiments showed that Survivin
downregulation was not due to decreased Survivin mRNA and
did not happen at the transcription level. Nevertheless, an effect
on endogenous Survivin pre-mRNA cannot be rejected. Our
results suggested that Pin1 regulation occurred at least at the
protein level. Pin1 mutation of Ser 16 to Glu had an inhibitory
effect on Survivin modulation. This mutation inactivated the
binding capacity of Pin1 on target proteins. Thus p(Ser/Thr)–Pro
recognition is needed for Pin1 overexpression-induced effect.
Nevertheless, mutation of the only p(Ser/Thr)–Pro site of
Survivin (Thr34–Ala) did not abolish Pin1 overexpression
outcome. Pin1–Survivin interaction rather seemed indirect. It is
conceivable that Pin1 could indirectly modulate Survivin levels
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proteins.
Co-immunoprecipitation in neuroblastoma cells demon-
strated that Pin1 and Survivin could be part of a common
protein complex. Partial co-immunolocalization in neuroblas-
toma cells further illustrated Pin1 and Survivin close relation-
ship. It is worth noting that only a small fraction of Pin1 has been
found in complex with Survivin. This result is in accord with the
fact that Pin1 only transiently interacts with its substrates. This
could also be explained because Pin1 downregulated Survivin.
There are numerous protein complexes where Pin1 and
Survivin can be found together with common protein partners.
During mitosis, Survivin associates with Aurora B and INCENP
on the centromere/kinetochore to form a chromosomal passenger
complex [22]. Aurora B and INCENP have been described as
Pin1 partners [52]. Aurora B has twoThr–Pro sites [53] including
the phylogenetically conserved Thr35 (found in many ortho-/
homo-logs with the exception of rodents) which may allow Pin1
binding. In addition, Pin1 has already been related to Plk1 which
is involved in the regulation of the chromosomal passenger
complex [54,55]. Pin1 and Survivin could also interact at
microtubules and centrosome level. Survivin binds to micro-
tubules [21]. Pin1 copurifies with γ-tubulin and localizes to
centrosome [56]. Overexpression of Pin1 in mouse mammary
glands potently induces centrosome amplification, eventually
leading to mammary hyperplasia and malignant mammary
tumors with overamplified centrosomes [56]. Pin1 downregula-
tion of Survivin could sustain these results as Survivin colocali-
zes with caspase3 and p21WAF1/CIP1 within centrosome and as
interference with Survivin expression or function causes cell-
division defect characterized by centrosome deregulation, multi-
polar mitotic spindles and multinucleated, polyploid cells [57].
In conclusion, the functional interactions between Pin1 and
Survivin may be of particular interest in oncogenesis and cell
division. Further studies will be needed to better understand the
mechanisms by which Pin1 and Survivin interact and their
consequences.
Acknowledgements
This work was supported by Inserm, CNRS, IMPRT, Uni-
versity of Lille 2, Lille County Hospital (CHRU-Lille), Région
Nord/Pas-de-Calais, FEDER, APOPIS (contract LSHM-CT-
2003-503330), GIS-Longévité and Fédération pour la Recherche
sur le Cerveau. Pierre Dourlen and Kunie Ando are recipients of a
scholarship from the French Research Ministry and the French
ForeignAffairsMinistry respectively. Human Survivin cDNA is a
kind gift of Professor Altieri, Worcester, USA. Authors are
grateful to Nathalie Jouy, Martial Flactif and Harold Fauvel
(Institut de Médecine Prédictive et Recherche Thérapeutique,
IFR114, Lille, France) for their technical supports.
References
[1] R. Ranganathan, K.P. Lu, T. Hunter, J.P. Noel, Structural and functional
analysis of the mitotic rotamase Pin1 suggests substrate recognition is
phosphorylation dependent, Cell 89 (1997) 875–886.[2] M.B. Yaffe, M. Schutkowski, M. Shen, X.Z. Zhou, P.T. Stukenberg, J.U.
Rahfeld, J. Xu, J. Kuang, M.W. Kirschner, G. Fischer, L.C. Cantley, K.P.
Lu, Sequence-specific and phosphorylation-dependent proline isomeriza-
tion: a potential mitotic regulatory mechanism, Science 278 (1997)
1957–1960.
[3] K.P. Lu, Pinning down cell signaling, cancer and Alzheimer's disease,
Trends Biochem. Sci. 29 (2004) 200–209.
[4] P.J. Lu, G. Wulf, X.Z. Zhou, P. Davies, K.P. Lu, The prolyl isomerase Pin1
restores the function of Alzheimer-associated phosphorylated tau protein,
Nature 399 (1999) 784–788.
[5] X.Z. Zhou, O. Kops, A. Werner, P.J. Lu, M. Shen, G. Stoller, G. Kullertz,
M. Stark, G. Fischer, K.P. Lu, Pin1-dependent prolyl isomerization
regulates dephosphorylation of Cdc25C and tau proteins, Mol. Cell 6
(2000) 873–883.
[6] C. Smet, A.V. Sambo, J.M. Wieruszeski, A. Leroy, I. Landrieu, L. Buee,
G. Lippens, The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the
phospho-Thr212–Pro213 site on Tau, Biochemistry 43 (2004) 2032–2040.
[7] C. Smet, J.M.Wieruszeski, L. Buee, I. Landrieu, G. Lippens, Regulation of
Pin1 peptidyl–prolyl cis/trans isomerase activity by its WW binding
module on a multi-phosphorylated peptide of Tau protein, FEBS Lett. 579
(2005) 4159–4164.
[8] I. Landrieu, C. Smet, J.M. Wieruszeski, A.V. Sambo, R. Wintjens, L. Buee,
G. Lippens, Exploring the molecular function of PIN1 by nuclear magnetic
resonance, Curr. Protein Pept. Sci. 7 (2006) 179–194.
[9] M. Hamdane, P. Dourlen, A. Bretteville, A.V. Sambo, S. Ferreira, K. Ando,
O. Kerdraon, S. Begard, L. Geay, G. Lippens, N. Sergeant, A. Delacourte,
C.A. Maurage, M.C. Galas, L. Buee, Pin1 allows for differential Tau
dephosphorylation in neuronal cells, Mol. Cell. Neurosci. 32 (2006)
155–160.
[10] M.C. Galas, P. Dourlen, S. Begard, K. Ando, D. Blum, M. Hamdane,
L. Buee, The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-
induced dephosphorylation of Tau in neurons. Implication in a patho-
logical mechanism related to Alzheimer disease, J. Biol. Chem. 281
(2006) 19296–19304.
[11] M. Hamdane, C. Smet, A.V. Sambo, A. Leroy, J.M.Wieruszeski, P. Delobel,
C.A. Maurage, A. Ghestem, R. Wintjens, S. Begard, N. Sergeant, A.
Delacourte, D. Horvath, I. Landrieu, G. Lippens, L. Buee, Pin1: a therapeutic
target in Alzheimer neurodegeneration, J. Mol. Neurosci. 19 (2002)
275–287.
[12] M. Hamdane, P. Delobel, A.V. Sambo, C. Smet, S. Begard, A. Violleau,
I. Landrieu, A. Delacourte, G. Lippens, S. Flament, L. Buee, Neurofibrillary
degeneration of the Alzheimer-type: an alternate pathway to neuronal
apoptosis? Biochem. Pharmacol. 66 (2003) 1619–1625.
[13] Y.C. Liou, A. Ryo, H.K. Huang, P.J. Lu, R. Bronson, F. Fujimori, T. Uchida,
T. Hunter, K.P. Lu, Loss of Pin1 function in the mouse causes phenotypes
resembling cyclin D1-null phenotypes, Proc. Natl. Acad. Sci. U. S. A. 99
(2002) 1335–1340.
[14] G.M. Wulf, A. Ryo, G.G. Wulf, S.W. Lee, T. Niu, V. Petkova, K.P. Lu,
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in
increasing the transcriptional activity of c-Jun towards cyclin D1, EMBO J.
20 (2001) 3459–3472.
[15] A. Ryo, M. Nakamura, G. Wulf, Y.C. Liou, K.P. Lu, Pin1 regulates
turnover and subcellular localization of beta-catenin by inhibiting its
interaction with APC, Nat. Cell Biol. 3 (2001) 793–801.
[16] A. Ryo, F. Suizu, Y. Yoshida, K. Perrem, Y.C. Liou, G. Wulf, R. Rottapel,
S. Yamaoka, K.P. Lu, Regulation of NF-kappaB signaling by Pin1-
dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/
RelA, Mol. Cell 12 (2003) 1413–1426.
[17] M. Shen, P.T. Stukenberg, M.W. Kirschner, K.P. Lu, The essential mitotic
peptidyl–prolyl isomerase Pin1 binds and regulates mitosis-specific
phosphoproteins, Genes Dev. 12 (1998) 706–720.
[18] A.L. Albert, S.B. Lavoie, M. Vincent, Multisite phosphorylation of Pin1-
associated mitotic phosphoproteins revealed by monoclonal antibodies
MPM-2 and CC-3, BMC Cell Biol. 5 (2004) 22.
[19] K.P. Lu, S.D. Hanes, T. Hunter, A human peptidyl–prolyl isomerase
essential for regulation of mitosis, Nature 380 (1996) 544–547.
[20] D.S. O'Connor, N.R. Wall, A.C. Porter, D.C. Altieri, A p34(cdc2) survival
checkpoint in cancer, Cancer Cell 2 (2002) 43–54.
1437P. Dourlen et al. / Biochimica et Biophysica Acta 1773 (2007) 1428–1437[21] F. Li, G. Ambrosini, E.Y. Chu, J. Plescia, S. Tognin, P.C. Marchisio, D.C.
Altieri, Control of apoptosis and mitotic spindle checkpoint by survivin,
Nature 396 (1998) 580–584.
[22] S.P. Wheatley, A. Carvalho, P. Vagnarelli, W.C. Earnshaw, INCENP is
required for proper targeting of Survivin to the centromeres and the
anaphase spindle during mitosis, Curr. Biol. 11 (2001) 886–890.
[23] D.C. Altieri, The case for survivin as a regulator of microtubule dynamics
and cell-death decisions, Curr. Opin. Cell Biol. 18 (2006) 609–615.
[24] P. Zacchi, M. Gostissa, T. Uchida, C. Salvagno, F. Avolio, S. Volinia,
Z. Ronai, G. Blandino, C. Schneider, G. Del Sal, The prolyl isomerase Pin1
reveals amechanism to control p53 functions after genotoxic insults, Nature
419 (2002) 853–857.
[25] H. Zheng, H. You, X.Z. Zhou, S.A. Murray, T. Uchida, G. Wulf, L. Gu,
X. Tang, K.P. Lu, Z.X. Xiao, The prolyl isomerase Pin1 is a regulator of
p53 in genotoxic response, Nature 419 (2002) 849–853.
[26] E.B. Becker, A. Bonni, Pin1 mediates neural-specific activation of the
mitochondrial apoptotic machinery, Neuron 49 (2006) 655–662.
[27] Y. Jiang, A. de Bruin, H. Caldas, J. Fangusaro, J. Hayes, E.M. Conway,
M.L. Robinson, R.A. Altura, Essential role for survivin in early brain
development, J. Neurosci. 25 (2005) 6962–6970.
[28] C.D. Lu, D.C. Altieri, N. Tanigawa, Expression of a novel antiapoptosis
gene, survivin, correlated with tumor cell apoptosis and p53 accumulation
in gastric carcinomas, Cancer Res. 58 (1998) 1808–1812.
[29] P. Fortugno, N.R. Wall, A. Giodini, D.S. O'Connor, J. Plescia, K.M.
Padgett, S. Tognin, P.C. Marchisio, D.C. Altieri, Survivin exists in
immunochemically distinct subcellular pools and is involved in spindle
microtubule function, J. Cell Sci. 115 (2002) 575–585.
[30] P.J. Lu, X.Z. Zhou, Y.C. Liou, J.P. Noel, K.P. Lu, Critical role of WW
domain phosphorylation in regulating phosphoserine binding activity and
Pin1 function, J. Biol. Chem. 277 (2002) 2381–2384.
[31] D.S. O'Connor, D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S.
Tognin, P.C. Marchisio, D.C. Altieri, Regulation of apoptosis at cell
division by p34cdc2 phosphorylation of survivin, Proc. Natl. Acad. Sci.
U. S. A. 97 (2000) 13103–13107.
[32] N.R. Wall, D.S. O'Connor, J. Plescia, Y. Pommier, D.C. Altieri,
Suppression of survivin phosphorylation on Thr34 by flavopiridol
enhances tumor cell apoptosis, Cancer Res. 63 (2003) 230–235.
[33] D. Grossman, P.J. Kim, J.S. Schechner, D.C. Altieri, Inhibition of
melanoma tumor growth in vivo by survivin targeting, Proc. Natl. Acad.
Sci. U. S. A. 98 (2001) 635–640.
[34] M. Mesri, N.R. Wall, J. Li, R.W. Kim, D.C. Altieri, Cancer gene therapy
using a survivin mutant adenovirus, J. Clin. Invest. 108 (2001) 981–990.
[35] Z.J. Shen, S. Esnault, J.S. Malter, The peptidyl–prolyl isomerase Pin1
regulates the stability of granulocyte–macrophage colony-stimulating
factor mRNA in activated eosinophils, Nat. Immunol. 6 (2005) 1280–1287.
[36] A. Albert, S. Lavoie, M. Vincent, A hyperphosphorylated form of RNA
polymerase II is the major interphase antigen of the phosphoprotein
antibody MPM-2 and interacts with the peptidyl–prolyl isomerase Pin1,
J. Cell Sci. 112 (Pt 15) (1999) 2493–2500.
[37] J. Zhao, T. Tenev, L.M. Martins, J. Downward, N.R. Lemoine, The
ubiquitin–proteasome pathway regulates survivin degradation in a cell
cycle-dependent manner, J. Cell Sci. 113 (Pt 23) (2000) 4363–4371.
[38] L. Meng, R. Mohan, B.H. Kwok, M. Elofsson, N. Sin, C.M. Crews,
Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo anti-
inflammatory activity, Proc.Natl. Acad. Sci. U. S.A. 96 (1999) 10403–10408.
[39] F. van Drogen, O. Sangfelt, A. Malyukova, L. Matskova, E. Yeh, A.R.
Means, S.I. Reed, Ubiquitylation of cyclin E requires the sequentialfunction of SCF complexes containing distinct hCdc4 isoforms, Mol. Cell
23 (2006) 37–48.
[40] L. Bao, A. Kimzey, G. Sauter, J.M. Sowadski, K.P. Lu, D.G. Wang,
Prevalent overexpression of prolyl isomerase Pin1 in human cancers, Am.
J. Pathol. 164 (2004) 1727–1737.
[41] D.C. Altieri, Survivin, versatile modulation of cell division and apoptosis
in cancer, Oncogene 22 (2003) 8581–8589.
[42] C. Adida, C. Recher, E. Raffoux, M.T. Daniel, A.L. Taksin, P. Rousselot, F.
Sigaux, L. Degos, D.C. Altieri, H. Dombret, Expression and prognostic
significance of survivin in de novo acute myeloid leukaemia, Br. J.
Haematol. 111 (2000) 196–203.
[43] G. Ayala, D. Wang, G. Wulf, A. Frolov, R. Li, J. Sowadski, T.M. Wheeler,
K.P. Lu, L. Bao, The prolyl isomerase Pin1 is a novel prognostic marker in
human prostate cancer, Cancer Res. 63 (2003) 6244–6251.
[44] N. Zaffaroni, M. Pennati, M.G. Daidone, Survivin as a target for new
anticancer interventions, J. Cell. Mol. Med. 9 (2005) 360–372.
[45] K.P. Lu, Prolyl isomerase Pin1 as a molecular target for cancer diagnostics
and therapeutics, Cancer Cell 4 (2003) 175–180.
[46] G. Wulf, G. Finn, F. Suizu, K.P. Lu, Phosphorylation-specific prolyl
isomerization: is there an underlying theme? Nat. Cell Biol. 7 (2005)
435–441.
[47] E.S. Yeh, B.O. Lew, A.R. Means, The loss of PIN1 deregulates cyclin E
and sensitizes mouse embryo fibroblasts to genomic instability, J. Biol.
Chem. 281 (2006) 241–251.
[48] E. Yeh, M. Cunningham, H. Arnold, D. Chasse, T. Monteith, G. Ivaldi,
W.C. Hahn, P.T. Stukenberg, S. Shenolikar, T. Uchida, C.M. Counter, J.R.
Nevins, A.R. Means, R. Sears, A signalling pathway controlling c-Myc
degradation that impacts oncogenic transformation of human cells, Nat.
Cell Biol. 6 (2004) 308–318.
[49] J. Ma, H.K. Arnold, M.B. Lilly, R.C. Sears, A.S. Kraft, Negative
regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A,
Oncogene (2007).
[50] D. Haas, A.R. Ablin, C. Miller, S. Zoger, K.K. Matthay, Complete
pathologic maturation and regression of stage IVS neuroblastoma without
treatment, Cancer 62 (1988) 818–825.
[51] S. Esnault, Z.J. Shen, E.Whitesel, J.S.Malter, The peptidyl–prolyl isomerase
Pin1 regulates granulocyte–macrophage colony-stimulating factor mRNA
stability in T lymphocytes, J. Immunol. 177 (2006) 6999–7006.
[52] K.P. Lu, Y.C. Liou, X.Z. Zhou, Pinning down proline-directed phosphory-
lation signaling, Trends Cell Biol. 12 (2002) 164–172.
[53] J. Song, S. Salek-Ardakani, T. So, M. Croft, The kinases aurora B and
mTOR regulate the G1-S cell cycle progression of T lymphocytes, Nat.
Immunol. 8 (2007) 64–73.
[54] D.G. Crenshaw, J. Yang, A.R. Means, S. Kornbluth, The mitotic peptidyl–
prolyl isomerase, Pin1, interacts with Cdc25 and Plx1, EMBO J. 17 (1998)
1315–1327.
[55] H. Goto, T. Kiyono, Y. Tomono, A. Kawajiri, T. Urano, K. Furukawa, E.A.
Nigg, M. Inagaki, Complex formation of Plk1 and INCENP required for
metaphase–anaphase transition, Nat. Cell Biol. 8 (2006) 180–187.
[56] F. Suizu, A. Ryo, G. Wulf, J. Lim, K.P. Lu, Pin1 regulates centrosome
duplication, and its overexpression induces centrosome amplification,
chromosome instability, and oncogenesis, Mol. Cell Biol. 26 (2006)
1463–1479.
[57] F. Li, E.J. Ackermann, C.F. Bennett, A.L. Rothermel, J. Plescia, S. Tognin,
A. Villa, P.C. Marchisio, D.C. Altieri, Pleiotrophic cell-division defects
and apoptosis induced by interference with survivin function, Nat. Cell
Biol. 1 (1999) 461–466.
